Plant ID: NPO28926
Plant Latin Name: Corydalis tuberosa
Taxonomy Genus: Corydalis
Taxonomy Family: Papaveraceae
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
n.a.
China
DRD1; DRD2; | |
SLC22A2; | |
F3; LMNA; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
SLC superfamily of solute carriers | SLC22A2 | Solute carrier family 22 member 2 | O15244 | CHEMBL1743122 |
Small molecule receptor (family A GPCR) | DRD1 | Dopamine D1 receptor | P21728 | CHEMBL2056 |
Small molecule receptor (family A GPCR) | DRD2 | Dopamine D2 receptor | P14416 | CHEMBL217 |
Unclassified | F3 | Coagulation factor III | P13726 | CHEMBL4081 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.789E-11 | 9.739E-08 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.789E-11 | 9.739E-08 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.363E-11 | 9.739E-08 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 3.996E-10 | 1.450E-06 | CYP1A2, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 1.613E-09 | 3.025E-06 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 1.667E-09 | 3.025E-06 | CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
MF | GO:0005488; binding | GO:0020037; heme binding | 2.899E-09 | 4.508E-06 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 8.926E-09 | 1.023E-05 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.197E-08 | 1.241E-05 | CYP1A2, CYP2C19, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.322E-07 | 1.152E-04 | CYP1A2, CYP2C19, CYP2C9 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.760E-07 | 1.369E-04 | CYP1A2, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 7.235E-07 | 5.251E-04 | CYP2D6, CYP3A4 |
CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 2.059E-06 | 1.401E-03 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, DRD1 |
BP | Unclassified; | GO:0021853; cerebral cortex GABAergic interneuron migration | 2.410E-06 | 1.500E-03 | DRD1, DRD2 |
CC | GO:0016020; membrane | GO:0031090; organelle membrane | 5.223E-06 | 2.774E-03 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, DRD1, DRD2, LMNA |
BP | GO:0023052; signaling | GO:0051584; regulation of dopamine uptake involved in synaptic transmission | 6.743E-06 | 3.415E-03 | DRD1, DRD2 |
BP | GO:0032501; multicellular organismal process | GO:0030432; peristalsis | 1.083E-05 | 5.127E-03 | DRD1, DRD2 |
BP | GO:0032502; developmental process | GO:0021756; striatum development | 1.323E-05 | 6.132E-03 | DRD1, DRD2 |
BP | GO:0051179; localization | GO:0015872; dopamine transport | 1.588E-05 | 6.779E-03 | DRD1, SLC22A2 |
BP | GO:0007610; behavior | GO:0007625; grooming behavior | 1.588E-05 | 6.779E-03 | DRD1, DRD2 |
MF | GO:0060089; molecular transducer activity | GO:0004952; dopamine neurotransmitter receptor activity | 1.588E-05 | 6.779E-03 | DRD1, DRD2 |
BP | GO:0050896; response to stimulus | GO:0060134; prepulse inhibition | 1.876E-05 | 7.427E-03 | DRD1, DRD2 |
BP | GO:0009987; cellular process | GO:0060158; phospholipase C-activating dopamine receptor signaling pathway | 1.876E-05 | 7.427E-03 | DRD1, DRD2 |
MF | GO:0005488; binding | GO:0035240; dopamine binding | 1.876E-05 | 7.427E-03 | DRD1, DRD2 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 6.750E-17 | 1.470E-12 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
CC | GO:0043226; organelle | GO:0097730; non-motile cilium | 1.187E-04 | 3.356E-02 | DRD1, DRD2 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 1.048E-10 | 3.250E-09 | CYP2C9, CYP2D6, CYP1A2, CYP3A4, CYP2C19 |
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 7.439E-10 | 1.153E-08 | CYP2C9, CYP1A2, CYP3A4, CYP2C19 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 3.373E-08 | 3.486E-07 | CYP2C9, CYP2D6, CYP1A2, CYP3A4 |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 5.409E-08 | 4.192E-07 | CYP2C9, CYP1A2, CYP3A4, CYP2C19 |
09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 3.868E-06 | 2.398E-05 | CYP2C9, CYP1A2, CYP3A4 |
09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 1.994E-05 | 1.030E-04 | CYP2C9, CYP2D6, CYP2C19 |
09160 Human Diseases | 09164 Substance dependence | hsa05030 | Cocaine addiction | 2.613E-04 | 1.157E-03 | DRD1, DRD2 |
09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 4.187E-04 | 1.442E-03 | CYP2C9, CYP2C19 |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 3.664E-04 | 1.420E-03 | CYP1A2, CYP3A4 |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 8.418E-04 | 2.610E-03 | DRD1, DRD2 |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 2.276E-03 | 5.426E-03 | CYP2C9, CYP1A2, CYP2C19, CYP3A4 |
09150 Organismal Systems | 09156 Nervous system | hsa04728 | Dopaminergic synapse | 1.796E-03 | 5.061E-03 | DRD1, DRD2 |
09160 Human Diseases | 09163 Neurodegenerative diseases | hsa05012 | Parkinson's disease | 2.170E-03 | 5.426E-03 | DRD1, DRD2 |
09160 Human Diseases | 09164 Substance dependence | hsa05034 | Alcoholism | 3.419E-03 | 7.067E-03 | DRD1, DRD2 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 4.206E-03 | 8.149E-03 | DRD1, DRD2 |
09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 2.498E-03 | 5.531E-03 | CYP1A2 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | DRD2; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | DRD2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Carcinoid syndrome | E34.0 | DRD2; |
J00-J99: Diseases of the respiratory system | Bronchitis | J20-J21, J42 | DRD2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | DRD1; |
NA: NA | Itching | NA | DRD2; |
NA: NA | Vomiting | NA | DRD2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | DRD2; |
NA: NA | Benign prostatic hypertrophy | NA | DRD2; |
I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F3; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | DRD1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD1; DRD2; |
NA: NA | Malignant essential hypertension | NA | DRD2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | DRD1; |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | DRD2; |
I00-I99: Diseases of the circulatory system | Hypotension | I95 | DRD2; |
I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | DRD1; DRD2; |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | DRD2; |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | DRD2; |
J00-J99: Diseases of the respiratory system | Asthma | J45 | DRD2; |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | DRD2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Acromegaly | E22.0 | DRD2; |
C00-D49: Neoplasms | Breast cancer | C50 | DRD2; |
NA: NA | False perceptions | NA | DRD2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperprolactinemia | E22.1 | DRD2; |
NA: NA | Corneal vascularity | NA | DRD2; |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | DRD2; |
G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6; |
NA: NA | Peripheral vasoconstriction | NA | DRD2; |
O00-O9A: Pregnancy, childbirth and the puerperium | Postpartum haemorrhage | O72 | DRD2; |
I00-I99: Diseases of the circulatory system | Pulmonary hypertension | I27.0, I27.2 | DRD2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD1; DRD2; |
J00-J99: Diseases of the respiratory system | Adult respiratory distress syndrome | J80 | F3; |
NA: NA | Schizoaffective disorders | NA | DRD2; |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | DRD1; DRD2; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | DRD1; DRD2; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | F3; |
NA: NA | Hyperaemia | NA | DRD2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | DRD2; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | DRD2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychosis | F20-F29 | DRD2; |
K00-K95: Diseases of the digestive system | Gastrointestinal problems | K30-K31, Q40-Q41 | DRD2; |
H00-H59: Diseases of the eye and adnexa | Ophthalmic disease | H00-H59 | DRD2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | DRD2; |
A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | DRD2; |
I00-I99: Diseases of the circulatory system | Maintain blood pressure in hypotensive states | I10 | DRD2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | DRD2; |
I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | DRD2; |
K00-K95: Diseases of the digestive system | Dermal necrosis | K05 | DRD2; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Depressive fatigue | R53.82 | DRD2; |
NA: NA | Malignant phaeochromocytoma | NA | DRD2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Advanced stage Parkinson's disease | F02.3, G20 | DRD2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | DRD2; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | DRD2; |
J00-J99: Diseases of the respiratory system | Nasal congestion | J34.89 | DRD2; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | DRD2; |
O00-O9A: Pregnancy, childbirth and the puerperium | Excessive bleeding following childbirth and spontaneous or elective abortion | O04 | DRD1; |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Idiopathic thrombocytopenic purpura | D69.3 | DRD2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | DRD1; |
G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | DRD2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD1; DRD2; |
I00-I99: Diseases of the circulatory system | Cardiotonic | I50 | DRD2; |
I00-I99: Diseases of the circulatory system | Cardiac failure | I50 | DRD2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; DRD2; |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | DRD2; |
NA: NA | Inflammatory diseases | NA | DRD2; |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | DRD2; |